Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Seagen Inc.
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.

Number of employees : 1 605 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Pharmaceutical Products654.70100%916.71100% +40.02%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States654.70100%916.71100% +40.02%
Managers
NameAgeSinceTitle
Clay Siegall582004Chairman, President & Chief Executive Officer
Todd E. Simpson582005Chief Financial Officer
Vaughn Himes582016Chief Technical Officer
Robert J. Lechleider, Dr.-2016Senior Vice President-Clinical Development
Roger D. Dansey, Dr.622018Chief Medical Officer
Marc E. Lippman, Dr.742000Independent Director
Felix James Baker, Dr.502005Lead Independent Director
David W. Gryska632005Independent Director
Daniel Welch612007Independent Director
Nancy A. Simonian, Dr.582012Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 180,306,390 179,210,233 99.4% 0 0.0% 99.4%
Shareholders
NameEquities%
Baker Bros. Advisors LP 47,269,424 27.2%
Capital Research & Management Co. (International Investors) 18,636,304 10.7%
Capital Research & Management Co. (Global Investors) 11,322,570 6.51%
The Vanguard Group, Inc. 10,829,389 6.22%
T. Rowe Price Associates, Inc. (Investment Management) 9,214,128 5.30%
PRIMECAP Management Co. 5,750,582 3.31%
Wellington Management Co. LLP 5,658,675 3.25%
JPMorgan Investment Management, Inc. 4,558,547 2.62%
Cascade Investment LLC 3,521,088 2.02%
Bill & Melinda Gates Foundation Trust (Investment Management) 3,021,088 1.74%
Company contact information
Seagen Inc.
21823-30th Drive SE
Bothell, WA 98021

Phone : +1.425.527.4000
Web : http://www.seattlegenetics.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
SEAGEN INC.49.05%30 708
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.82.04%41 055
IQVIA HOLDINGS INC.9.37%32 400
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION-4.66%18 514
ALNYLAM PHARMACEUTICALS, INC.12.80%15 093
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 061
PPD, INC.0.00%12 238
BIO-TECHNE CORPORATION38.18%11 711
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.50.67%11 666
PHARMARON BEIJING CO., LTD.83.22%11 024
QIAGEN N.V.42.78%11 009
ICON PUBLIC LIMITED COMPANY13.15%10 285
ACADIA PHARMACEUTICALS INC.32.45%9 008
CRISPR THERAPEUTICS AG108.39%8 967
GALAPAGOS NV-44.69%8 055
PRA HEALTH SCIENCES, INC.0.94%7 198
NOVAVAX, INC.3,058.04%7 134
IONIS PHARMACEUTICALS, INC.-16.35%7 065